• Proliferation Tracing Reveals Mechanisms of Breast Tumor Rel

  2026-04-20

  This study introduces a dual recombinase-based mouse model enabling precise tracing and ablation of proliferating cells in spontaneous breast cancer, emulating clinical relapse dynamics. By integrating single-cell transcriptomics, it uncovers how dormant, therapy-resistant cell populations and microenvironmental changes drive tumor recurrence—offering a robust platform for evaluating anti-relapse interventions.

• CP-673451: Selective PDGFRα/β Inhibitor for Advanced Cancer

  2026-04-19

  CP-673451 stands out as a precision tool for dissecting PDGFR-mediated signaling in cancer, offering unmatched selectivity and translational relevance, especially in ATRX-deficient glioma studies. This article delivers actionable insights, protocol upgrades, and troubleshooting strategies that empower researchers to maximize the impact of this selective PDGFRα/β inhibitor.

• Dextrose (D-glucose): Reliable Solutions for Cell Assays

  2026-04-18

  This article addresses common laboratory challenges in cell viability, proliferation, and metabolic assays, illustrating how Dextrose (D-glucose) (SKU A8406) serves as a highly reproducible, data-backed solution. Drawing on protocol parameters, literature, and real-world scenarios, it offers practical guidance for biomedical researchers and lab technicians seeking robust assay performance.

• Immune Signature Modulation by Epigenetic Inhibitors in Mela

  2026-04-17

  Anichini et al. provide a comparative landscape of immune-related transcriptional signatures induced by different epigenetic inhibitors in melanoma cell models, revealing that DNMT inhibition via guadecitabine robustly upregulates innate immune pathways. These findings inform rational strategies for combining epigenetic drugs with immunotherapy to overcome resistance in melanoma and potentially other cancers.

• NHS-Biotin for Precision Protein Labeling in Advanced Resear

  2026-04-16

  NHS-Biotin (N-hydroxysuccinimido biotin) stands out for its efficient, membrane-permeable biotinylation—enabling reliable protein labeling even in complex, multimeric nanobody systems. This article delivers actionable protocol guidance and troubleshooting insights, translating recent breakthroughs in protein engineering into robust, reproducible workflows.

• GANT61: GLI Inhibitor Workflows for Cancer Immunotherapy Res

  2026-04-15

  GANT61 empowers researchers to selectively inhibit GLI1/2, unlocking new experimental strategies for studying tumor immune evasion and resistance. This guide delivers actionable workflows, troubleshooting insights, and data-driven protocol enhancements—making GANT61 from APExBIO a pivotal asset in next-generation cancer research.

• Cy3-UTP for Nucleotide-Level RNA Dynamics: Methods and Impac

  2026-04-14

  Explore how Cy3-UTP enables nucleotide-resolution analysis of RNA conformational changes and interaction studies. This article reveals unique methodological insights and practical assay considerations for fluorescence-based RNA research.

• Vitamin C in Advanced Organoid and Anticancer Assays

  2026-04-13

  Vitamin C (ascorbic acid) is redefining experimental standards as both an anticancer agent and a workflow enhancer in organoid-based virology research. Leveraging APExBIO’s high-purity formulation ensures reliable, reproducible results in complex multi-lineage models where traditional protocols fall short.

• Tamoxifen as a Selective Estrogen Receptor Modulator: Applie

  2026-04-13

  Tamoxifen’s dual identity as a selective estrogen receptor modulator and a molecular toolkit for gene knockout makes it indispensable for translational and preclinical research. This article delivers stepwise workflow enhancements, troubleshooting guidance, and protocol intelligence to help researchers maximize experimental reliability and impact.

• 3-Bromopyruvate Sensitizes Cetuximab-Resistant CRC via Ferro

  2026-04-12

  This study demonstrates that 3-bromopyruvate (3-BP), when combined with cetuximab, overcomes resistance in colorectal cancer (CRC) cells by activating autophagy-dependent ferroptosis and apoptosis. The findings highlight FOXO3a pathway restoration as central to this synergistic effect, offering a mechanistic framework for tackling therapeutic resistance in KRAS/BRAF mutant or acquired-resistant CRC.

• SIX1-Driven Lipogenesis Regulation in Liver Cancer: Mechanis

  2026-04-12

  This study uncovers how the transcription factor SIX1 directly induces de novo lipogenesis (DNL) in liver cancer cells by upregulating key lipogenic enzymes through chromatin acetylation. The findings clarify a previously uncharacterized regulatory axis involving DGUOK-AS1, microRNA-145-5p, and SIX1, with significant implications for targeted liver cancer therapies.

• Practical Guide: Calpain Inhibitor I, ALLN in Apoptosis & In

  2026-04-11

  Calpain Inhibitor I, ALLN offers researchers a reliable, selective tool for inhibiting calpain I/II and cathepsin B/L in mechanistic apoptosis, inflammation, and ischemia-reperfusion injury studies. This compound is best employed in cell-based and in vivo models where precise protease control is required, but is not intended for diagnostic or clinical use.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Optimizing Immunoass

  2026-04-11

  The Cy3 Goat Anti-Human IgG (H+L) Antibody transforms human IgG detection across immunofluorescence, IHC, flow cytometry, and ELISA, delivering robust sensitivity and reproducibility. Discover actionable protocols, advanced applications, and troubleshooting tactics that empower researchers to extract maximum value from every experiment.

• Verteporfin: Redefining Photodynamic and Autophagy Pathwa...

  2026-04-10

  This thought-leadership article unpacks the dual mechanistic action of Verteporfin—both as a photosensitizer for photodynamic therapy and a light-independent autophagy inhibitor. Drawing from recent advances in surface ectoderm biology and YAP-TEAD super-enhancer networks, we offer actionable guidance for translational researchers in ocular neovascularization, age-related macular degeneration, and cancer research. We contextualize APExBIO Verteporfin’s capabilities, integrate recent evidence, and chart a visionary path for next-generation experimental design.

• Polymyxin B (sulfate) (SKU C3090): Reliable Solutions for...

  2026-04-09

  This scenario-driven article addresses real-world laboratory challenges in cell viability, cytotoxicity, and Gram-negative bacterial infection assays. Drawing on validated protocols and the unique properties of Polymyxin B (sulfate) (SKU C3090), it demonstrates how researchers can achieve reproducible results and enhanced sensitivity in the face of multidrug resistance. Evidence-based comparisons position SKU C3090 as a robust, reliable choice for advanced biomedical research workflows.

10314 records 8/688 page Previous Next First page 上5页 678910 下5页 Last page